Amylin receptor agonism thus emerges as an attractive therapeutic target, with the selective amylin receptor agonist eloralintide achieving -20% weight loss with the 9-mg dose after 48 weeks in a phase 2 trial [15]
Results Most clients notice reduced appetite within the first 12 weeks, with steady, sustainable weight loss over time
Ongoing follow-up is completed monthly via a secure form sent by text, with continued communication to assess progress, side effects, and determine whether dose adjustments are needed
Whether you're a healthcare professional, a patient dealing with obesity, or simply someone interested in weight loss, this article is for you
These patches do not contain GLP-1 ingredients, but the name is used as a marketing tactic to associate them with the effectiveness of real GLP-1 medications